Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telpegfilgrastim for prevention of chemotherapy-induced neutropenia in breast cancer
ChiCTR2400090997Phase 4Not yet recruiting
- Sponsor
- 307 Hospital of the People's Liberation Army
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegfilgrastim in neutropenia, febrile neutropenia (FN) and breast cancer, sponsored by 307 Hospital of the People's Liberation Army. Primary endpoint: Incidence of grade ≥3 neutropenia (ANC < 1.0 × 10^9/L) in cycle 1. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
pegfilgrastim
03
Conditions
neutropeniafebrile neutropenia (FN)breast cancer
Beyond the preview
Go deeper on ChiCTR2400090997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090997.